Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
1.330
-0.230 (-14.74%)
At close: Jun 27, 2025, 4:00 PM
1.340
+0.010 (0.73%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Aditxt Revenue
Aditxt had revenue of $1.02K in the quarter ending March 31, 2025, a decrease of -98.72%. This brings the company's revenue in the last twelve months to $55.32K, down -89.08% year-over-year. In the year 2024, Aditxt had annual revenue of $133.99K, down -79.23%.
Revenue (ttm)
$55.32K
Revenue Growth
-89.08%
P/S Ratio
4.54
Revenue / Employee
$2,128
Employees
26
Market Cap
2.82M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ADTX News
- 1 day ago - Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET - Business Wire
- 16 days ago - Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting - PRNewsWire
- 18 days ago - Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors - Business Wire
- 22 days ago - Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6 - Business Wire
- 5 weeks ago - Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Business Wire
- 2 months ago - Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Business Wire
- 2 months ago - Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™ - Business Wire
- 2 months ago - Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 - Business Wire